TetraLogic, Egalet seek $172.5m in IPOs; Relypsa ups deal value; Aerie, Ruthigen set price ranges
This article was originally published in Scrip
Executive Summary
Cancer-focused TetraLogic registered an initial public offering of up to $103.5m with the US Securities and Exchange Commission (SEC) and pain specialist Egalet filed for a $69m IPO to advance their lead drug candidates into late-stage clinical trials and raise cash before they run out of funds.